The enterprise refuses to produce "cheap and efficient" drugs because of its low profit

Recently, a number of hospitals in Chongqing have reported that they are in short supply of Cediland, protamine, and m-hydroxyamine Some hospitals can only borrow these drugs from other hospitals in order to save patients According to the reporter's investigation, these are some common drugs with low price and good effect The shortage of these drugs exists in many hospitals, even affects the daily rescue work of hospitals Hospitals need to rescue Cediland, protamine and m-hydroxyamine, which are commonly used drugs for cardiovascular disease and rescue They have more than ten years or even longer clinical experience They have been proved to have good curative effect and low price At present, there is no alternative medicine Xiong Yi, chief physician of the pharmacy department of the first people's Hospital of Shapingba District, Chongqing, said that the hospital estimated that about 50 pieces of xidilan injection were needed in one month, but the inventory of the pharmacy department was less than 10 In recent years, suppliers have reduced their supplies Unless they encounter critical patients, they can only use one for each patient What's more, some district and county hospitals and smaller hospitals have been in serious shortage of such drugs Jiangjin District People's hospital once sent a request to Chongqing Cancer Hospital, hoping to support this kind of medicine "We are also in short supply We want to borrow it from a large hospital Now I can't borrow it, and there's a shortage of big hospitals " The city cancer hospital pharmacy said Reporters visited a number of hospitals to learn that, in addition to Cediland, protamine and m-hydroxyamine, other drugs with good efficacy and low price are also in short supply, some of which have even died out or are dying out In the process of purchasing these drugs, they are often told by the manufacturers that they are short of raw materials and do not produce them for the time being Why does the enterprise refuse to produce these good drugs with good clinical effect and low price gradually disappear? Many hospital staff interviewed said that due to the low price, the profit of drug manufacturers is meager, or even no profit, and the number of manufacturers is getting smaller and smaller Even if the production is also regular production, the output is also very small, so it is necessary to find a relationship to get a small amount of drugs According to the person in charge of Chongqing drug exchange, Cediland, protamine, m-hydroxyamine and other drugs are in short supply all over the country, and there are few manufacturers The institute once recruited enterprises for cheap and efficient old drugs, and actively invited enterprises to enter the platform of Chongqing drug exchange, but the enterprises refused According to expert analysis, most of these drugs that are disappearing are basic drugs and commonly used drugs Under the current framework of drug pricing and purchasing system, these drugs can be said to be "sacrificed" or "disappeared" On the one hand, how to protect the government? Under the current system of limiting the price of essential drugs and winning the bid at low price in drug purchase, the price of these drugs has not been raised reasonably, and the profit space of enterprises has been squeezed, which leads to the fact that they produce less or even do not produce these drugs On the other hand, some of the disappeared drugs have high price substitutes, and enterprises can make more profits by producing and selling such new drugs How to get out of the dilemma? Experts suggest that the state and local governments should introduce preferential policies and protection measures for relevant production enterprises, not only to ensure the reasonable profit space of enterprises, but also to ensure that low-cost and high-efficiency drugs will not disappear, and can continue to be used to cure diseases and save people The head of Chongqing pharmaceutical exchange suggested that for the basic drugs with good curative effect and low price, the state should consider setting factories, pricing and quantitative production, and compensate pharmaceutical enterprises and hospitals at the same time, otherwise such drugs would disappear, and patients would have to spend more money to buy more expensive drugs In addition, to further improve the drug pricing mechanism, we cannot blindly pursue low-cost bid winning.